Biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases.
Regeneron Pharmaceuticals, Inc. is a pioneering biotechnology company engaged in the discovery, development, and commercialization of transformative medicines worldwide. Established in 1988 and headquartered in Tarrytown, New York, Regeneron is renowned for its innovative products that address a wide spectrum of diseases. The company's portfolio includes EYLEA, which targets conditions such as neovascular age-related macular degeneration and diabetic retinopathy, and Dupixent, an advanced treatment for atopic dermatitis and asthma across both adult and pediatric populations. Additionally, Regeneron's groundbreaking REGEN-COV therapy has been pivotal in combating COVID-19, underscoring its commitment to addressing global health challenges.
Regeneron Pharmaceuticals, Inc. not only delivers critical treatments but also continuously pushes the boundaries of biotechnology with ongoing research and development initiatives. Beyond its commercial successes, the company maintains a robust pipeline of product candidates spanning areas such as eye diseases, allergic and inflammatory conditions, cardiovascular disorders, infectious diseases, and rare genetic conditions. This breadth of focus is supported by strategic collaborations with industry leaders like Sanofi, Bayer, and Roche, as well as partnerships with government entities and academic institutions, reinforcing Regeneron's role as a leader in biopharmaceutical innovation.
Driven by a mission to improve patient outcomes through scientific excellence and technological innovation, Regeneron Pharmaceuticals, Inc. remains at the forefront of biomedical research. With a steadfast dedication to advancing healthcare solutions, the company continues to redefine possibilities in treating cancer, pain management, hematologic disorders, and beyond, shaping the future of medicine worldwide.